Maria-Anna Ortner1. 1. Department of Gastroenterology, UVCM, University Hospital Inselspital, Freiburgerstrasse, Bern, Switzerland.
Abstract
PURPOSE OF REVIEW: Photodynamic therapy (PDT) with hematoporphyrins has emerged as promising treatment for nonresectable cholangiocarcinoma in several prospective observational studies and two randomized studies. This review describes the mechanism of action of PDT, gives an overview of clinical experience in cholangiocarcinoma and summarizes the results published in 2007 and 2008. RECENT FINDINGS: The mechanism of action of PDT has been further elucidated. PDT induces an apoptotic, antiangiogenic as well as an immunomodulatory response. Interleukin-6, a bile duct epithelium growth factor correlating with tumor burden, decreases after PDT. The efficacy of PDT was confirmed in a comparative study in the United States. Patients with no visible mass on imaging studies, high serum albumin levels and treatment immediately after diagnosis seem to benefit most from PDT. Although it is recommended to perform PDT in bile ducts without stents in place, illumination through metal stents is possible if the light dose is adjusted. Meso-tetrahydroxyphenyl chlorine is a new potent photosensitizer for PDT of cholangiocarcinoma. SUMMARY: In advanced nonresectable cholangiocarcinoma, PDT is the only evidence-based treatment that improves survival when compared with stenting. Therefore, PDT should be offered to those who are unsuitable for surgery.
PURPOSE OF REVIEW: Photodynamic therapy (PDT) with hematoporphyrins has emerged as promising treatment for nonresectable cholangiocarcinoma in several prospective observational studies and two randomized studies. This review describes the mechanism of action of PDT, gives an overview of clinical experience in cholangiocarcinoma and summarizes the results published in 2007 and 2008. RECENT FINDINGS: The mechanism of action of PDT has been further elucidated. PDT induces an apoptotic, antiangiogenic as well as an immunomodulatory response. Interleukin-6, a bile duct epithelium growth factor correlating with tumor burden, decreases after PDT. The efficacy of PDT was confirmed in a comparative study in the United States. Patients with no visible mass on imaging studies, high serum albumin levels and treatment immediately after diagnosis seem to benefit most from PDT. Although it is recommended to perform PDT in bile ducts without stents in place, illumination through metal stents is possible if the light dose is adjusted. Meso-tetrahydroxyphenyl chlorine is a new potent photosensitizer for PDT of cholangiocarcinoma. SUMMARY: In advanced nonresectable cholangiocarcinoma, PDT is the only evidence-based treatment that improves survival when compared with stenting. Therefore, PDT should be offered to those who are unsuitable for surgery.
Authors: Christopher A Wadsworth; Peter H Dixon; Jason H Wong; Michael H Chapman; Siobhan C McKay; Amar Sharif; Duncan R Spalding; Stephen P Pereira; Howard C Thomas; Simon D Taylor-Robinson; John Whittaker; Catherine Williamson; Shahid A Khan Journal: Dig Dis Date: 2011-06-17 Impact factor: 2.404
Authors: Aksana Höblinger; T Gerhardt; M A Gonzalez-Carmona; R Hüneburg; T Sauerbruch; V Schmitz Journal: Eur J Med Res Date: 2011-09-12 Impact factor: 2.175
Authors: Eliana Alves; Maria A F Faustino; João P C Tomé; Maria G P M S Neves; Augusto C Tomé; José A S Cavaleiro; Ângela Cunha; Newton C M Gomes; Adelaide Almeida Journal: PLoS One Date: 2011-06-17 Impact factor: 3.240